Patents Assigned to Encysive Pharmaceuticals Inc.
  • Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
    Patent number: 7812038
    Abstract: A method for the inhibition of the binding of ?4?1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and to the use of such compounds either a above, or in formulations for the control or prevention of diseases states in which ?4?1 is involved.
    Type: Grant
    Filed: June 14, 2005
    Date of Patent: October 12, 2010
    Assignee: Encysive Pharmaceuticals, Inc.
    Inventors: Ronald J. Biediger, Qi Chen, E. Radford Decker, George W. Holland, Jamal M. Kassir, Wen Li, Robert V. Market, Ian L. Scott, Chengde Wu, Jian Li
  • Processes for the preparation of N-(2-acetyl-4,6-dimethylphenyl)-3-{[(3,4 dimethyl-5-isoxazolyl)amino]sulfonyl}-2-thiophenecarboxamide
    Patent number: 7754892
    Abstract: Provided are processes for the preparation of N-(2-acetyl-4,6-dimethylphenyl)-3-{[(3,4 dimethyl-5-isoxazolyl)amino]sulfonyl}-2-thiophenecarboxamide, a compound useful for the treatment of endothelin-mediated disorders.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: July 13, 2010
    Assignee: Encysive Pharmaceuticals, Inc.
    Inventor: John F. Reichwein
  • Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
    Patent number: 7320989
    Abstract: The present invention relates to urotensin II receptor antagonists, pharmaceutical compositions containing them and their use.
    Type: Grant
    Filed: August 23, 2004
    Date of Patent: January 22, 2008
    Assignee: Encysive Pharmaceuticals, Inc.
    Inventors: Eric Anderson, Brian Dupre, Daxin Gao, Raymond J. Kessler, Wen Li, Chengde Wu
  • Phenylenediamine Urotensin-II receptor antagonists and CCR-9 antagonists
    Patent number: 7319111
    Abstract: The present invention relates to urotensin II receptor antagonists, CCR-9 antagonists, pharmaceutical compositions containing them and their use.
    Type: Grant
    Filed: February 18, 2004
    Date of Patent: January 15, 2008
    Assignee: Encysive Pharmaceuticals, Inc.
    Inventors: Daxin Gao, Robert Market, Chengde Wu
  • Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
    Patent number: 7288538
    Abstract: The present invention relates to urotensin II receptor antagonists, CCR-9 antagonists, pharmaceutical compositions containing them and their use.
    Type: Grant
    Filed: August 23, 2004
    Date of Patent: October 30, 2007
    Assignee: Encysive Pharmaceuticals, Inc.
    Inventors: Chengde Wu, Daxin Gao, Ronald Biediger, Jie Chen, Robert V. Market
  • Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
    Patent number: 7265122
    Abstract: The present invention relates to urotensin II receptor antagonists, pharmaceutical compositions containing them and their use.
    Type: Grant
    Filed: February 20, 2004
    Date of Patent: September 4, 2007
    Assignee: Encysive Pharmaceuticals, Inc.
    Inventors: Chengde Wu, C. Eric Anderson, Huong Bui, Brian Dupre, Daxin Gao, George W. Holland, Jamal Kassir, Wen Li, Junmei Wang
  • Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds
    Publication number: 20070060608
    Abstract: A composition, method and kit comprising a compound for the inhibition of the binding of ?4?1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin and other therapeutic compounds for the control or prevention of diseases states in which ?4?1 is involved.
    Type: Application
    Filed: November 7, 2003
    Publication date: March 15, 2007
    Applicants: ENCYSIVE PHARMACEUTICALS INC., SCHERING CORPORATION
    Inventors: Peter Vanderslice, George Holland, Neng Shih, Robert Asianian, Richard Chapman, William Kreutner
  • Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
    Patent number: 6972296
    Abstract: A method for the inhibition of the binding of ?4?1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and to the use of such compounds either a above, or in formulations for the control or prevention of diseases states in which ?4?1 is involved.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: December 6, 2005
    Assignee: Encysive Pharmaceuticals Inc.
    Inventors: Ronald J. Biediger, Qi Chen, E. Radford Decker, George W. Holland, Jamal M. Kassir, Wen Li, Robert V. Market, Ian L. Scott, Chengde Wu, Jian Li
  • Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
    Publication number: 20040180892
    Abstract: The present invention relates to urotensin II receptor antagonists, CCR-9 antagonists, pharmaceutical compositions containing them and their use.
    Type: Application
    Filed: February 18, 2004
    Publication date: September 16, 2004
    Applicant: Encysive Pharmaceuticals Inc.
    Inventors: Chengde Wu, C. Eric Anderson, Huong Bui, Daxin Gao, Jamal Kassir, Wen Li, Junmei Wang, Robert V. Market
  • Sulfonamides and derivatives thereof that modulate the activity of endothelin
    Patent number: 6686382
    Abstract: Thienyl-, furyl-, pyrrolyl- and phenylsulfonamides, formulations of pharmaceutically-acceptable derivatives thereof and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides, N-(isoxazolyl)pyrrolylsulfonamides and N-(isoxazolyl)phenylsulfonamides, formulations thereof and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or pharmaceutically acceptable derivatives thereof that inhibit the activity of endothelin are also provided.
    Type: Grant
    Filed: December 29, 2000
    Date of Patent: February 3, 2004
    Assignee: Encysive Pharmaceuticals Inc.
    Inventors: Chengde Wu, Natalie Blok, George W. Holland
  • Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
    Patent number: 6613804
    Abstract: Biphenylsulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, bicyclic or tricyclic carbon or heterocyclic ring biphenylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.
    Type: Grant
    Filed: December 4, 2001
    Date of Patent: September 2, 2003
    Assignee: Encysive Pharmaceuticals, Inc.
    Inventors: Ming Fai Chan, Timothy Kogan, Erik Joel Verner, Adam Kois, Vitukudi Narayanaiyengar Balaji